“So I'd say that's probably an opportunity for us to maybe break out of that higher end 6% range going forward.”

In context

“pectation on that. You'll have a little bit of a partial year impact there of some pricing that we took across the entire Nutrition portfolio. So I'd say we're probably above that 4% to 6% range that we used to have prepandemic, at least into 2024. As I've said, I think that we can be at the higher end of that range once everything kind of settles down. And I think a big growth driver for us going forward is really going to be the Adult segment, which is growing high-single digits and of which we've got very high market share positions across the globe. And this position with the brand we have, the science that we have, really aligns to, I'd say, a pretty sustainable demographic trend that we're seeing, which is just an aging population that is focusing on Healthcare and on Nutrition. So I'd say that's probably an opportunity for us to maybe break out of that higher end 6% range going forward. But I think right now, you'll see the impact of the share in the U.S., some partial year impact of the price allow us to be above that 6% range. And then as we move into next year, what's going to be the impact of some of the launches that we have planned for the Adult segment and what is that going to do for us? Operator: And our next question will come from Vijay Kumar with Evercore ISI. Vijay Kumar: Robert, congratulations on a nice Q4 and a solid guide. I guess my one question is on M&A. Looking at the balance sheet phenomenal position, you at least have a minimum of $20 billion of firepower, Abbott hasn't done any large deals in the last few years. So my question is, how do you see the opportunity for larger-sized deals, what is Abbott's appetite for a larger-sized, more meaningful”